{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.7","upperLimit":"39.3","value":"32.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)","id":"OG000","title":"AZD6244"}],"paramType":"MEDIAN","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"Every cycle during treatment, then every 3 months for the first 2 years, then every six months for the next three years and then annually for the next 5 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}